LANTIBIOTIC VARIANTS AND USES THEREOF
First Claim
Patent Images
1. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising a mutation including:
- a. arginine at position 13 changed to asparagine (R13N);
b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y);
c. asparagine at position 18 changed to alanine (N18A);
d. tyrosine at position 20 changed to phenylalanine (Y20F);
ore. combinations thereof.
7 Assignments
0 Petitions
Accused Products
Abstract
The disclosure relates to lantibiotic structural variants that have improved antimicrobial properties when compared to wild-type lantibiotics, and uses thereof. Embodiments include non-naturally occurring lantibiotics.
1 Citation
103 Claims
-
1. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising a mutation including:
-
a. arginine at position 13 changed to asparagine (R13N); b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y); c. asparagine at position 18 changed to alanine (N18A); d. tyrosine at position 20 changed to phenylalanine (Y20F);
ore. combinations thereof. - View Dependent Claims (47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 71, 72, 103)
-
-
2. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising two mutations, wherein one mutation includes:
-
a. arginine at position 13 changed to asparagine (R13N); b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y); c. asparagine at position 18 changed to alanine (N18A); d. tyrosine at position 20 changed to phenylalanine (Y20F);
ore. combinations thereof. - View Dependent Claims (3, 4)
-
-
5. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising two mutations, wherein one mutation includes:
-
a. phenylalanine at position 1 changed to valine (F1V); b. phenylalanine at position 1 changed to alanine (F1A); c. phenylalanine at position 1 changed to isoleucine (F1I); d. phenylalanine at position 1 changed to leucine (F1L); e. phenylalanine at position 1 changed to threonine (F1T);
orf. phenylalanine at position 1 changed to tyrosine (F1Y). - View Dependent Claims (6, 7)
-
-
8. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising two mutations including:
-
a. phenylalanine at position 1 changed to alanine in combination with arginine at position 13 changed to; i. alanine (F1A R13A), ii. valine (F1A R13V), iii. asparagine (F1A R13N), or iv. serine(F1A R13S); b. phenylalanine at position 1 changed to glycine in combination with arginine at position 13 changed to; i. glycine (F1G R13G); c. phenylalanine a position 1 changed to histidine in combination with arginine at position 13 changed to; i. asparagine (F1H R13N); d. phenylalanine at position 1 changed to isoleucine in combination with arginine at position 13 changed to; i. alanine (F1I R13A), ii. glycine (F1I R13G), iii. isoleucine (F1I R13I), iv. asparagine (F1I R13N), v. proline (F1I R13P), vi. glutamine (F1I R13Q), vii. glutamic acid (F1I R13S), viii. serine (F1R13V), or ix. valine (F1I R13E); e. phenylalanine at position 1 changed to leucine in combination with arginine at position 13 changed to; i. alanine (F1L R13A), ii. aspartic acid (F1L R13D), iii. glycine (F1L R13G), iv. asparagine (F1L R13N), v. proline (F1L R13P), or vi. glutamine (F1L R13Q); f. phenylalanine at position 1 changed to threonine in combination with arginine at position 13 changed to; i. alanine (F1T R13A), ii. asparagine (F1T R13N), or iii. valine (F1T R13V); g. phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to; i. alanine (F1V R13A), ii. asparagine (F1V R13N), iii. glutamine (F1V R13Q), iv. aspartic acid (F1V R13D), v. valine (F1V R13V), or vi. proline (F1V R13P);
orh. phenylalanine at position 1 changed to tyrosine in combination with arginine at position 13 changed to; i. aspartic acid (F1Y R13D), or ii. glycine (F1Y R13G). - View Dependent Claims (9, 10)
-
-
11. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising three mutations including:
-
a. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with glycine at position 15 changed to alanine (F1I R13A G15A); b. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with glycine at position 15 changed to alanine (F1I R13D G15A); c. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to isoleucine, in combination with arginine at position 13 changed to alanine (F1I W4I R13A); d. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to aspartic acid (F1I W4M R13D); e. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to asparagine (F1I W4M R13N); f. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with arginine at position 13 changed to alanine (F1I K2A R13A); g. phenylalanine at position 1 changed to isoleucine, in combination with leucine at position 6 changed to valine, in combination with arginine at position 13 changed to alanine (F1I L6V R13A); h. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13A Y20F); i. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13D Y20F); j. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13N Y20F); k. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13N Y20F); l. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13A Y20F);
orm. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13D Y20F).
-
-
12. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising mutations wherein:
-
a. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to alanine (F1I K2A W4K R13A);
orb. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to aspartic acid (F1I K2A W4K R13D).
-
-
13. A non-naturally occurring lantibiotic comprising an amino acid sequence of MU1140 and further comprising mutations wherein phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I K2A W4K R13A Y20F).
-
14. A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO:
- 1156) and further comprising a mutation including;
a. arginine at position 13 changed to asparagine (R13N); b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y); c. asparagine at position 18 changed to alanine (N18A); d. tyrosine at position 20 changed to phenylalanine (Y20F);
ore. combinations thereof.
- 1156) and further comprising a mutation including;
-
15. A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO:
- 1156) and further comprising two mutations, wherein one mutation includes;
a. arginine at position 13 changed to asparagine (R13N); b. phenylalanine at position 17 changed to leucine (F17L) or tyrosine (F17Y); c. asparagine at position 18 changed to alanine (N18A); d. tyrosine at position 20 changed to phenylalanine (Y20F);
ore. combinations thereof. - View Dependent Claims (16, 17)
- 1156) and further comprising two mutations, wherein one mutation includes;
-
18. A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO:
- 1156) and further comprising two mutations, wherein one mutation includes;
a. phenylalanine at position 1 changed to valine (F V); b. phenylalanine at position 1 changed to alanine (F1A); c. phenylalanine at position 1 changed to isoleucine (F1I); d. phenylalanine at position 1 changed to leucine (F1L); e. phenylalanine at position 1 changed to threonine (F1T);
orf. phenylalanine at position 1 changed to tyrosine (F1Y). - View Dependent Claims (19, 20)
- 1156) and further comprising two mutations, wherein one mutation includes;
-
21. A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO:
- 1156) and further comprising two mutations including;
a. phenylalanine at position 1 changed to alanine in combination with arginine at position 13 changed to; i. alanine (F1A R13A), ii. valine (F1A R13V), iii. asparagine (F1A R13N), or iv. serine(F1A R13S); b. phenylalanine at position 1 changed to glycine in combination with arginine at position 13 changed to; i. glycine (F1G R13G); c. phenylalanine a position 1 changed to histidine in combination with arginine at position 13 changed to; i. asparagine (F1H R13N); d. phenylalanine at position 1 changed to isoleucine in combination with arginine at position 13 changed to; i. alanine (F1I R13A), ii. glycine (F1I R13G), iii. isoleucine (F1I R13I), iv. asparagine (F1I R13N), v. proline (F1I R13P), vi. glutamine (F1I R13Q), vii. glutamic acid (F1I R13S), viii. serine (F1I R13V), or ix. valine (F1I R13E); e. phenylalanine at position 1 changed to leucine in combination with arginine at position 13 changed to; i. alanine (F1L R13A), ii. aspartic acid (F1L R13D), iii. glycine (F1L R13G), iv. asparagine (F1L R13N), v. proline (F1L R13P), or vi. glutamine (F1L R13Q); f. phenylalanine at position 1 changed to threonine in combination with arginine at position 13 changed to; i. alanine (F1T R13A), ii. asparagine (F1T R13N), or iii. valine (F1T R13V); g. phenylalanine at position 1 changed to valine in combination with arginine at position 13 changed to; i. alanine (F1V R13A), ii. asparagine (F1V R13N), iii. glutamine (F1V R13Q), iv. aspartic acid (F1V R13D), v. valine (F1V R13V), or vi. proline (F1V R13P);
orh. phenylalanine at position 1 changed to tyrosine in combination with arginine at position 13 changed to; i. aspartic acid (F1Y R13D), or ii. glycine (F1Y R13G). - View Dependent Claims (22, 23)
- 1156) and further comprising two mutations including;
-
24. A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO:
- 1156) and further comprising three mutations including;
a. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with glycine at position 15 changed to alanine (F1I R13A G15A); b. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with glycine at position 15 changed to alanine (F1I R13D G15A); c. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to isoleucine, in combination with arginine at position 13 changed to alanine (F1I W4I R13A); d. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to aspartic acid (F1I W4M R13D); e. phenylalanine at position 1 changed to isoleucine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to asparagine (F1I W4M R13N); f. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with arginine at position 13 changed to alanine (F1I K2A R13A); g. phenylalanine at position 1 changed to isoleucine, in combination with leucine at position 6 changed to valine, in combination with arginine at position 13 changed to alanine (F1I L6V R13A); h. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13A Y20F); i. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13D Y20F); j. phenylalanine at position 1 changed to isoleucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1I R13N Y20F); k. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to asparagine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13N Y20F); l. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13A Y20F);
orm. phenylalanine at position 1 changed to leucine, in combination with arginine at position 13 changed to aspartic acid, in combination with tyrosine at position 20 changed to phenylalanine (F1L R13D Y20F).
- 1156) and further comprising three mutations including;
-
25. A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO:
- 1156) and further comprising mutations wherein;
a. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to alanine (F1I K2A W4K R13A);
orb. phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to lysine, in combination with arginine at position 13 changed to aspartic acid (F1I K2A W4K R13D).
- 1156) and further comprising mutations wherein;
-
26. A non-naturally occurring, post-translationally modified lantibiotic comprising an amino acid sequence of MU1140 (SEQ ID NO:
- 1156) and further comprising mutations wherein phenylalanine at position 1 changed to isoleucine, in combination with lysine at position 2 changed to alanine, in combination with tryptophan at position 4 changed to methionine, in combination with arginine at position 13 changed to alanine, in combination with tyrosine at position 20 changed to phenylalanine (F1I K2A W4K R13A Y20F).
- 27. A non-naturally occurring lantibiotic comprising a single amino acid mutation of MU1140, the lantibiotic having an amino acid sequence encoded by of any one of SEQ ID NOS:
-
28. A non-naturally occurring lantibiotic comprising multisite amino acid mutations of MU1140, the lantibiotic being a variant as described in
FIG. 7 .
-
29. A non-naturally occurring lantibiotic comprising any variant as described in
FIG. 8 :- Group 1, Group 2 or Group 3.
-
30. A non-naturally occurring lantibiotic comprising any variant as described in
FIG. 8 :- Group 1.
-
31. A non-naturally occurring lantibiotic comprising a single amino acid mutation of MU1140 as described in
FIG. 6 .
-
32. A non-naturally occurring lantibiotic comprising an amino acid sequence of SEQ ID NO. 550.
-
44. An isolated lantibiotic variant, wherein the isolated lantibiotic variant is produced in a host cell by expressing a polypeptide from a polynucleotide encoding a lantibiotic variant of
FIG. 5 orFIG. 7 , and wherein the expressed polypeptide is post-translationally modified in the host cell.
- 46. A post-translationally modified, non-naturally occurring lantibiotic comprising an amino acid sequence of SEQ ID NO. 1157.
-
93. A purified polynucleotide comprising any one of SEQ ID NOs:
- 2-431 or encoding a variant as described in
FIG. 7 or combinations thereof.
- 2-431 or encoding a variant as described in
-
94. A purified polynucleotide comprising any one of SEQ ID NOs:
- 756, 757, 758, 759, or 760.
-
95. A purified polynucleotide comprising any one of SEQ ID NOs:
- 709, 714, 716, 735, 747, 751, 754, or 758.
-
96. A purified polynucleotide comprising SEQ ID NO:
- 758.
-
97. A purified polynucleotide comprising SEQ ID NO:
- 1163.
-
98. A host cell comprising a polynucleotide of SEQ ID NO:
- 758.
-
99. A host cell comprising a polynucleotide of SEQ ID NO:
- 1163.
-
100. An isolated recombinant Streptococcus mutans strain comprising a polynucleotide of SEQ ID NO:
- 758.
-
101. An isolated recombinant Streptococcus mutans strain comprising a polynucleotide of SEQ ID NO:
- 1163.
-
102. A non-naturally occurring polypeptide comprising an amino acid sequence of SEQ ID NO. 1161.
Specification